Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioconNSE:BIOCON -0.79%89 Days Payable is 441.62 as of Mar. 2026, which is 91% above its 10-year median of 230.99. GuruFocus rates NSE:BIOCON with a GF Score™ of 89/100 and a GF Value™ of ₹339.48 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 702 Biotechnology companies, Biocon ranks better than 77.21% on this metric.
Biocon's average Accounts Payable for the
three
months ended in Mar. 2026 was ₹67,721 Mil. Biocon's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹13,993 Mil.
Hence, Biocon's Days Payable for the
three
months ended in Mar. 2026 was 441.62.
The historical rank and industry rank for Biocon's Days Payable or its related term are showing as below:
NSE:BIOCON'
s Days Payable Range Over the Past 10 Years
Min: 170.02 Med: 230.99 Max: 450.13
Current: 433.94
During the past 13 years, Biocon's highest Days Payable was 450.13. The lowest was 170.02. And the median was 230.99.
NSE:BIOCON's Days Payable is ranked better than 77.21% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs NSE:BIOCON: 433.94
Biocon's Days Payable
increased
from Mar. 2025 (405.71) to Mar. 2026 (441.62).
It may suggest that Biocondelayed paying its suppliers.
Biocon Days Payable Related Terms
Biocon Days Payable Historical Data
* Premium members only.
The historical data trend for Biocon's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BIOCON vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Biocon's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocon Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biocon's Days Payable distribution charts can be found below:
* The bar in red indicates where Biocon's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Biocon's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocon (NSE:BIOCON) has a Days Payable of 441.62 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biocon and its competitors. This is 91% above median its historical median of 230.99. Over the past decade, Biocon's Days Payable has ranged from 170.02 to 450.13. According to the industry distribution chart, Biocon ranks #160 out of 702 companies in the Biotechnology industry, placing it in the top 22.8%.
Is Biocon's Days Payable too high?
Biocon's current Days Payable of 441.62 is 91% above median its 10-year median of 230.99. Over the past 10 years, this metric has ranged from a low of 170.02 to a high of 450.13. The Biotechnology industry median Days Payable is 113.10. Biocon's value of 441.62 is 290.5% above this industry median. Based on the distribution chart, Biocon ranks #160 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Biocon has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocon's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocon ranks #160 out of 702 companies for Days Payable. This places Biocon in the top 23% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Biocon's value of 441.62 is 290.5% above this benchmark. Historically, Biocon's own Days Payable has ranged from 170.02 to 450.13 over the past decade. While the company's 10-year median is 230.99 vs. the industry median of 113.10, Biocon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocon's current Days Payable of 441.62 is 290.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biocon and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocon's current Days Payable is 441.62, which is 91% above median its own 10-year median of 230.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocon stock overvalued right now?
Based on GuruFocus' analysis, Biocon (NSE:BIOCON) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹339.48, compared to a current price of ₹437.20 — trading 28.8% above its estimated fair value. The current Days Payable is 441.62, which is 91% above median its 10-year median of 230.99 and 290.5% above the Biotechnology industry median of 113.10. Biocon's overall GF Score™ is 89/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biocon (NSE:BIOCON), the current Days Payable is 441.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocon (NSE:BIOCON) Overvalued in 2026?
Based on GuruFocus' analysis, Biocon stock appears to be overvalued.
The current stock price of ₹437.20 is trading 28.8% above its estimated GF Value™ of ₹339.48.
GuruFocus considers Biocon to be Modestly Overvalued.
Key valuation signals for NSE:BIOCON:
Days Payable: 441.62 (91% above median its 10-year median of 230.99)
GF Value™: ₹339.48 vs. price of ₹437.20 (28.8% above fair value)
Industry Position: 290.5% above the Biotechnology median (#160 of 702)
No single metric tells the full story. See the NSE:BIOCON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
89GF Score
Get the complete analysis for NSE:BIOCON
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BIOCON has been successfully added to your 
